menu
    • menu
    [{"orgOrder":0,"company":"Edgewood Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewood Oncology Reports Efficacy Data from BTX-A51 Study in Liposarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"BTX-A51","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Edgewood Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Edgewood Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Edgewood Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Edgewood Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewood Doses First Patients In Phase 2a Study Of BTX-A51 For Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"BTX-A51","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Edgewood Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Edgewood Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewood Oncology \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Edgewood Oncology

    Menu

    Edgewood Oncology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Edgewood Oncology

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed

                            Edgewood Oncology

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BTX-A51

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Edgewood Doses First Patients In Phase 2a Study Of BTX-A51 For Breast Cancer

                            Details : BTX-A51 is a first-in-class, small molecule, multi-selective kinase inhibitor of casein kinase 1 alpha as well as the transcriptional regulators CDK7 and CDK9. It is being evaluated for liposarcoma.

                            Brand Name : BTX-A51

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 21, 2024

                            Lead Product(s) : BTX-A51

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Edgewood Oncology

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed

                            Edgewood Oncology

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BTX-A51

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Edgewood Oncology Reports Efficacy Data from BTX-A51 Study in Liposarcoma

                            Details : BTX-A51 is a first-in-class small molecule inhibiting CK1α, CDK7, and CDK9, currently being evaluated for treating liposarcoma.

                            Brand Name : BTX-A51

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 07, 2024

                            Lead Product(s) : BTX-A51

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth